Pharmafile Logo
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • - PMLiVE
  • Communiqué 53 Cover Image

muscle loss

- PMLiVE

Regeneron announces results for preventing lean mass and muscle loss during GLP-1 weight loss

Results show trevogrumab prevents lean mass and muscle loss during GLP-1 weight loss

- PMLiVE

Regeneron’s New Drug Application for cemdisiran accepted for review by FDA and EMA

Globally, around 150 to 200 out of every million people have myasthenia gravis

- PMLiVE

Regeneron agrees research collaboration with Parabilis Medicines

Regeneron will pay Parabilis $125m upfront, with up to $2.2bn in potential milestone payments and royalties

- PMLiVE

Sanofi and Regeneron’s Dupixent receives positive NICE final draft guidance for COPD

Around 1.4 million people in the UK are diagnosed with COPD, with two million thought to be undiagnosed

- PMLiVE

Regeneron’s Libtayo receives EC approval for skin cancer

Phase 3 trial results showed the drug significantly improved disease-free survival

- PMLiVE

Eli Lilly’s oral weight-loss candidate orforglipron shows promise in late-stage trial

The company is planning to submit the candidate for regulatory review by the end of the year

- PMLiVE

Sanofi/Regeneron’s Dupixent granted FDA approval for bullous pemphigoid

Around 27,000 adults in the US are living with uncontrolled cases of the chronic skin disease

- PMLiVE

Sanofi/Regeneron share results for Dupixent in atopic dermatitis patients with darker skin tones

These are the first clinical study results for the drug in a large population of patients with darker skin tones

regeneron headquarters

Regeneron’s bispecific antibody Lynozyfic approved by EC to treat multiple myeloma

More than 35,000 new cases of the blood cancer are diagnosed in Europe every year

- PMLiVE

Sanofi/Regeneron’s Dupixent granted FDA approval for chronic spontaneous urticaria

More than 300,000 people in the US are living with uncontrolled cases of the inflammatory skin disease

- PMLiVE

Sanofi and Regeneron’s Dupixent granted FDA priority review for bullous pemphigoid

Approximately 27,000 adults in the US are living with uncontrolled cases of the skin disease

- PMLiVE

Merck gains rights to Hansoh’s preclinical GLP-1 candidate in deal worth $2bn

The company will evaluate the asset’s potential to provide cardiometabolic benefits beyond weight reduction

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links